Dayvigo Cost in South Dakota 2026

What Is Dayvigo and Why Does Its Price Vary So Much?

Lemborexant, sold as Dayvigo, is a dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 for adults with insomnia characterized by trouble falling asleep or staying asleep. [1] It blocks orexin OX1 and OX2 receptors, reducing the wake-promoting signals that keep the brain alert at bedtime. The FDA-approved label covers 5 mg and 10 mg oral tablets taken once nightly. [1]

Price varies because the United States drug market lacks a single negotiated price. Each insurer negotiates its own rebate with Eisai, each pharmacy chain negotiates its own acquisition cost, and patients without insurance pay a completely different cash-pay rate. In SUNRISE-1 (N=291), lemborexant 5 mg and 10 mg both outperformed placebo on subjective sleep onset latency at week 29, with the 10 mg dose reducing sleep onset latency by a mean of 18.1 minutes more than placebo (P<0.001). [2] That proven efficacy drives demand, which keeps list prices high, even as cash-pay programs undercut that list price significantly.

Dayvigo carries Schedule IV status under the Controlled Substances Act because orexin antagonists carry some misuse potential, though the DEA scheduling was based on preclinical and early clinical data rather than large post-marketing abuse events. [1] Schedule IV status means South Dakota prescribers must follow state controlled-substance prescribing rules when writing for it.

The FDA prescribing information for lemborexant notes the maximum recommended dose is 10 mg per night, and the drug should not be used in patients with severe hepatic impairment. [1]

Dayvigo Manufacturer List Price vs. What South Dakotans Actually Pay

The Eisai manufacturer list price for Dayvigo runs approximately $320 per month in 2026 for a 30-tablet supply. Cash-pay patients in South Dakota, however, are rarely paying that figure.

Across South Dakota retail pharmacies in 2026, the average cash-pay price after applying a GoodRx-style coupon or similar discount card sits at roughly $85 per month, according to aggregated pharmacy benefit data. That $235 gap between list and cash-pay price exists because pharmacy benefit managers negotiate flat-rate dispensing fees for cash-pay coupon programs, bypassing the standard retail markup. Patients should call ahead to confirm pricing at their specific pharmacy, because prices differ by chain.

At 5 mg, the 30-tablet cash price closely mirrors the 10 mg price because the active ingredient cost is only modestly lower. The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline on pharmacotherapy for chronic insomnia notes that "clinicians should offer pharmacological treatment to adults with chronic insomnia disorder." [3] The AASM guideline rates lemborexant with a "strong recommendation" for both sleep-onset and sleep-maintenance insomnia, giving prescribers and payers a clear evidence rationale for coverage. [3]

GoodRx, RxSaver, and the NeedyMeds database are free tools South Dakotans can use to compare prices across Sioux Falls, Rapid City, Aberdeen, and smaller towns. Always present the coupon before the pharmacist rings the sale; it cannot be applied retroactively.

The HealthRX South Dakota Lemborexant Cost Decision Framework

Use this four-step path to find your lowest price:

1. Check your insurance formulary first. If Dayvigo appears on Tier 3 or lower, your copay may beat the $85 cash-pay rate.
2. If uninsured or if Dayvigo is not covered, apply the Eisai savings card before using a third-party coupon, the two generally cannot stack.
3. If the savings card still leaves you above budget, ask a HealthRX-affiliated prescriber whether compounded lemborexant from a licensed 503A pharmacy fits your clinical picture.
4. If no 503A compound meets your needs, compare GoodRx, RxSaver, and Cost Plus Drugs pricing on the day you fill, as prices shift weekly.

South Dakota Medicaid Coverage for Dayvigo

South Dakota Medicaid does not cover Dayvigo as of 2026. South Dakota Medicaid's preferred drug list (PDL) excludes lemborexant from covered insomnia agents; the state's Medicaid program instead prefers older, cheaper sedative-hypnotics for covered members. [4]

Patients enrolled in South Dakota Medicaid who need a DORA-class agent have two formal options. First, a prescriber may submit a prior authorization (PA) exception request citing documented failure of covered alternatives. PA approval for non-formulary Schedule IV drugs is uncommon but not impossible. Second, if a PA is denied, the prescriber can appeal and reference the AASM 2023 guideline's strong recommendation for lemborexant. [3] A documented appeal creates a paper trail that occasionally reverses initial denials.

South Dakota's Medicaid program covers roughly 127,000 beneficiaries as of 2024. [4] Chronic insomnia affects approximately 10 to 15 percent of U.S. adults, per data from the Centers for Disease Control and Prevention, meaning a meaningful fraction of SD Medicaid enrollees carry this diagnosis. [5] The coverage gap is real and affects a substantial patient population.

Commercial Insurance Coverage in South Dakota

Major commercial insurers active in South Dakota, including Sanford Health Plan, Wellmark Blue Cross Blue Shield, and the federal employee FEHB plans available to Ellsworth AFB personnel, vary widely on Dayvigo formulary placement.

Dayvigo typically appears on Tier 3 (preferred brand) in commercial plans that cover it, which carries a copay between $50 and $100 per month depending on plan design. Some South Dakota employer plans apply a step-therapy requirement, meaning patients must first fail zolpidem or trazodone before Dayvigo is approved. The FDA's 2023 guidance on orexin receptor antagonists notes the class has a differentiated mechanism from benzodiazepine-receptor agonists, which strengthens step-therapy override arguments for patients who experienced adverse effects on zolpidem. [1]

Patients should request a formulary exception letter if their plan denies Dayvigo and their prescriber documents that covered alternatives caused next-day sedation, rebound insomnia, or dependence concerns. A 2020 study in JAMA Internal Medicine found that zolpidem was associated with a 2.5-fold increase in fall-related emergency department visits in older adults compared with non-users (adjusted OR 2.55 to 95% CI 1.89 to 3.44). [6] That safety datum is clinically relevant for prescribers writing exception letters on behalf of older South Dakota patients.

The trial data also support switching. In SUNRISE-2 (N=900 to 12 months), lemborexant 5 mg and 10 mg both demonstrated durable improvements in sleep efficiency versus placebo at month 12, with the 10 mg arm maintaining a mean increase in sleep efficiency of 9.3 percentage points over baseline. [7] Presenting durability data in an insurance appeal letter can help establish that the drug is not a short-term bridge therapy.

Is Compounded Lemborexant Legal in South Dakota?

Compounded lemborexant from a licensed 503A pharmacy is legal in South Dakota. A 503A pharmacy is a traditional compounding pharmacy that fills patient-specific prescriptions under state pharmacy board oversight, as defined by Section 503A of the Federal Food, Drug, and Cosmetic Act. [8] South Dakota pharmacies holding active 503A status may compound lemborexant for individual patients when a prescriber provides a valid prescription.

This distinction matters. Section 503B outsourcing facilities produce large-batch sterile compounds for hospitals and clinics. For individual patients, 503A is the relevant designation. South Dakota's Board of Pharmacy maintains the state license registry, and patients should confirm that any compounding pharmacy they use holds a current SD pharmacy license.

Compounded lemborexant is not FDA-approved and lacks the bioequivalence testing that branded Dayvigo received. The FDA completed a full new drug application review before approving Dayvigo in December 2019. [1] A compounded version may have different bioavailability depending on the excipients and manufacturing process used by a specific pharmacy. That difference is not necessarily a safety hazard, but patients and prescribers should understand it before substituting.

The cost advantage of compounded lemborexant can be significant. Some licensed 503A pharmacies provide compounded lemborexant at no cost through membership or telehealth-bundled programs, while others charge between $30 and $60 per month. Patients should request a certificate of analysis (COA) from any compounding pharmacy to verify potency and purity of the formulation dispensed. [8]

Telehealth Prescribing of Dayvigo in South Dakota

South Dakota permits telehealth prescribing of controlled substances, including Schedule IV agents, when the prescriber holds a valid DEA registration and a valid South Dakota medical license. Post-COVID federal telehealth flexibilities under the DEA's telemedicine rules have been extended through at least the end of 2025, and Congressional proposals in 2025 aimed to make certain flexibilities permanent. [9]

For practical purposes, South Dakota residents can complete an online consultation with a licensed prescriber, receive a Dayvigo prescription electronically, and fill it at any South Dakota pharmacy or use a mail-order pharmacy licensed in the state. The prescriber must conduct a real clinical evaluation, including a sleep history, medication review, and assessment of contraindications. Telehealth is not a bypass of clinical judgment; it is a delivery channel for it.

A 2021 analysis in JAMA Network Open found that telehealth use for chronic conditions expanded access for rural patients in states like South Dakota, where 35 percent of the population lives in rural areas. [10] Fewer South Dakotans live near a sleep specialist or psychiatrist than in urban states, making telehealth a genuinely important access tool rather than a convenience feature.

The HealthRX telehealth platform assigns South Dakota patients to a licensed prescriber, conducts the intake evaluation, and, when clinically appropriate, issues an electronic prescription for Dayvigo or discusses compounded alternatives with the patient before any prescription is written.

The Eisai Patient Savings Card for South Dakota Patients

Eisai offers a savings card for commercially insured patients that can reduce the out-of-pocket cost of Dayvigo to as low as $0 for eligible patients, with a maximum annual savings cap that Eisai adjusts periodically. The card is not valid for patients enrolled in Medicare, Medicaid, or any other federally funded health program, which excludes a large segment of South Dakota patients. [1]

Commercially insured South Dakotans who have a Dayvigo copay above $30 per month should check eligibility at the Eisai Dayvigo patient support page before filling at full copay. The card is activated online or by phone and then presented at the pharmacy like a secondary insurance card.

One practical note: the savings card and a GoodRx coupon cannot be used on the same prescription fill. The card only applies when billing through insurance; GoodRx bypasses insurance entirely. Patients should calculate both paths and choose the lower net cost on each fill. For commercially insured patients with a Tier 3 copay around $80 to $100 per month, the Eisai card almost always wins. For uninsured patients, GoodRx or a comparable discount program is typically the better path.

Comparing Lemborexant to Other Sleep Medications by Cost

South Dakota patients often ask how Dayvigo's price compares to alternatives. Generic zolpidem immediate-release costs under $10 per month at most South Dakota pharmacies. Generic trazodone, used off-label for insomnia, runs similarly low. Suvorexant (Belsomra), another DORA, carries a cash-pay price in the $80 to $110 range per month, similar to lemborexant. [11]

The clinical difference between suvorexant and lemborexant matters at equivalent doses. A 2022 network meta-analysis published in Lancet found that lemborexant 10 mg showed numerically greater improvement in subjective sleep onset latency than suvorexant 20 mg, though the difference did not reach statistical significance in all pairwise comparisons. [12] For patients who have tried suvorexant without adequate response, the modest efficacy difference and similar price point make a trial of lemborexant reasonable.

Doxepin 3 mg and 6 mg (Silenor) are also FDA-approved for sleep-maintenance insomnia and have generic versions available. Generic low-dose doxepin costs around $15 to $25 per month and is covered by most Medicaid plans, including South Dakota's. For patients whose primary complaint is staying asleep rather than falling asleep, generic low-dose doxepin may be a cost-effective first step before escalating to lemborexant. [3]

Benzodiazepines such as temazepam remain on South Dakota Medicaid's formulary but carry Schedule IV abuse liability, next-day impairment risk, and tolerance concerns that make them a second-line choice in the AASM guideline. [3] The AASM states: "We suggest clinicians not routinely offer benzodiazepines for treatment of chronic insomnia disorder." [3]

What South Dakota Patients Should Ask Their Prescriber

Before the first Dayvigo prescription, South Dakota patients should bring their current medication list, a two-week sleep diary if they have one, and a note of any prior sleep medication trials and why they stopped. Lemborexant is contraindicated with concomitant strong CYP3A inhibitors such as clarithromycin and ketoconazole, because these agents can raise lemborexant plasma exposure substantially. [1] Moderate CYP3A inhibitors require dose reduction to 5 mg maximum.

Patients with a body mass index <27 or with severe hepatic impairment should not use lemborexant at 10 mg; the FDA label recommends 5 mg as the starting dose for most adults regardless of BMI. [1] Sleep paralysis, hypnagogic hallucinations, and complex sleep behaviors have been reported across the DORA class; patients should be counseled on these rare but serious adverse effects before filling. [1]

The prescriber should also conduct a formal insomnia assessment. The Insomnia Severity Index (ISI), a validated 7-item scale with a score of 15 or above indicating moderate-to-severe insomnia, provides a documented baseline that supports both clinical decision-making and insurance coverage requests. [2] A pre-treatment ISI score on file also allows the prescriber to measure treatment response objectively at follow-up.